"The company has entered into an agreement with Hetero, under which Dr Reddy's has been licensed to distribute and market Sofosbuvir 400 mg tablets indicated in treatment of chronic Hepatitis C under the brand 'Resof' in India," the Hyderabad-based drug major said in a BSE filing.

Sofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.

Hetero had signed a non-exclusive agreement with Gilead Sciences to manufacture and sell its Hepatitis medicines.

"With the diagnosis rates for Hepatitis C in India being abysmally low, Dr Reddy's will make a significant difference in the diagnosis and treatment of this disease," the company cited.

The launch of Resof was in line with Dr Reddy's philosophy of innovative medicine at an affordable price and would provide significant relief to patients, resulting in potential cure and a high barrier to resistance at an affordable price for those living with Hepatitis C, Dr Reddy's Laboratories Co-Chairman and CEO G V Prasad assured.

Latest News  from Business News Desk